Local high-capacity adenovirus-mediated mCTLA4Ig and mCD40Ig expression prolongs recombinants gene expression in skeletal muscle

Molecular Therapy

Volumn 3, Issue 6, 2001, Pages 892-900

  Jiang, Zhi Long ^a   Reay, Daniel ^a   Kreppel, Florian ^c   Gambotto, Andrea ^a,b   Feingold, Eleanor ^a   Kochanek, Stefan ^c   McCarthy, Susan A ^a,b   Clemens, Paula R ^a,d  

^a UNIVERSITY OF PITTSBURGH GRADUATE SCHOOL OF PUBLIC HEALTH   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF COLOGNE   (Germany)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

High capacity adenoviral vector; Immune response; Murine CD40Ig; Murine CTLA4Ig

Indexed keywords

CAPSID PROTEIN; CD40 ANTIGEN; CELL PROTEIN; CYTOSKELETON PROTEIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GREEN FLUORESCENT PROTEIN; IMMUNOGLOBULIN G; MUSCLE PROTEIN; RECOMBINANT ANTIBODY; VIRUS CAPSID ANTIGEN; VIRUS PROTEIN; VIRUS VECTOR;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; GENE EXPRESSION; GENE INSERTION; GENE MUTATION; GENE TARGETING; GENE THERAPY; GENE TRANSFER; GENETIC CODE; GENETIC RECOMBINATION; HELPER VIRUS; HUMAN; HUMAN CELL; HYPOTHESIS; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; IN VIVO STUDY; INJECTION; MEDICAL RESEARCH; MOUSE; MUSCLE CELL; MUSCULAR DYSTROPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; SKELETAL MUSCLE; TIBIALIS ANTERIOR MUSCLE;

ADENOVIRIDAE; ANIMALIA; MIRIDAE; MURINAE;

EID: 0034952675     PISSN: 15250016     EISSN: None     Source Type: Journal    
DOI: 10.1006/mthe.2001.0331     Document Type: Article

References (49)

1. Transfer of genes to humans: Early lessons and obstacles to success
2. Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors
3. MHC class I-restricted cytotoxic T lymphocytes to viral antigens destroy hepatocytes in mice infected with E1-deleted recombinant adenoviruses
4. Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo
5. Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene therapy
6. Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therapy with recombinant adenoviruses
7. Transient immune blockade prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver
8. A new adenoviral vector: Replacement of all viral coding sequences with 28 kb of DNA independently expressing both full-length dystrophin and beta-galactosidase
9. High-capacity adenoviral vectors for gene transfer and somatic gene therapy
10. Encapsidated adenovirus minichromosomes allow delivery and expression of a 14 kb dystrophin cDNA to muscle cells
11. Administration of helper-dependent adenoviral vectors and sequential delivery of different vector serotype for long-term liver-directed gene transfer in baboons
12. Use of helper-dependent adenoviral vectors of alternative serotypes permits repeat vector administration
13. Use of a liver-specific promoter reduces immune response to the transgene in adenoviral vectors
14. Persistence in muscle of an adenoviral vector that lacks all viral genes
15. In vivo muscle gene transfer of full-length dystrophin with an adenoviral vector that lacks all viral genes
16. High doses of a helper-dependent adenoviral vector yield supraphysiological levels of alpha1-antitrypsin with negligible toxicity
17. An adenoviral vector deleted for all viral coding sequences results in enhanced safety and extended expression of a leptin transgene
18. Toxicity associated with repeated administration of first-generation adenovirus vectors does not occur with a helper-dependent vector
19. Genomic DNA transfer with a high-capacity adenovirus vector results in improved in vivo gene expression and decreased toxicity
20. Peripheral infection with adenovirus causes unexpected long-term brain inflammation in animals injected intracranially with first-generation, but not with high-capacity, adenovirus vectors: Toward realistic therapy for chronic diseases
21. Repeated administration of adenoviral vectors in lungs of human CD4 transgenic mice treated with a nondepleting CD4 antibody
22. Immunomodulation and adenoviral gene transfer to the lungs of nonhuman primates
23. Cyclophosphamide diminishes inflammation and prolongs transgene expression following delivery of adenoviral vectors to mouse liver and lung
24. Use of transient CD4 lymphocyte depletion to prolong transgene expression of E1-deleted adenoviral vectors
25. Nondepleting anti-CD4 antibody treatment prolongs lung-directed E1-deleted adenovirus-mediated gene expression in rats
26. Readministration of adenovirus vector in nonhuman primate lungs by blockade of CD40-CD40 ligand interactions
27. Prevention of immune reactions triggered by first-generation adenoviral vectors by monoclonal antibodies and CTLA41g
28. Combinatorial blockade of calcineurin and CD28 signalling facilitates primary and secondary therapeutic gene transfer by adenovirus vectors in dystrophic (mdx) mouse muscles
29. Local adenovirus-mediated CTLA4-immunoglobulin expression suppresses the immune responses to adenovirus vectors in the brain
30. Blunting of immune responses to adenoviral vectors in mouse liver and lung with CTLA41g
31. Transient immunomodulation with anti-CD40 ligand antibody and CTLA41g enhances persistence and secondary adenovirus-mediated gene transfer into mouse liver
32. Long-term hepatic adenovirus-mediated gene expression in mice following CTLA41g administration
33. Transient inhibition of CD28 and CD40 ligand interactions prolongs adenovirus-mediated transgene expression in the lung and facilitates expression after secondary vector administration
34. Transient subversion of CD40 ligand function diminishes immune responses to adenovirus vectors in mouse liver and lung tissues
35. A helper-dependent adenovirus vector system: Removal of helper virus by Cre-mediated excision of the viral packaging signal
36. Cellular immune response to adenoviral vector infected cells does not require de novo viral gene expression: Implications for gene therapy
37. Immune rejection of human dystrophin following intramuscular injections of naked DNA in mdx mice
38. Immune responses to dystrophin: Implications for gene therapy of Duchenne muscular dystrophy
39. CTLA-4-mediated inhibition of early events of T cell proliferation
40. Acquired thymic tolerance: Role of CTLA4 in the initiation and maintenance of tolerance in a clinically relevant autoimmune disease model
41. CTLA-4 engagement inhibits IL-2 accumulation and cell cycle progression upon activation of resting T cells
42. CTLA41g inhibits T cell-dependent B-cell maturation in murine systemic lupus erythematosus
43. CD40L blockade prevents autoimmune encephalomyelitis and hampers TH1 but not TH2 pathway of T cell differentiation
44. CTLA-4 ligation blocks CD28-dependent T cell activation
45. CD40 ligand (CD154) enhances the Th1 and antibody responses to respiratory syncytial virus in the BALB/c mouse
46. IRES-dependent second gene expression is significantly lower than cap-dependent first gene expression in a bicistronic vector
47. Effective repeat administration with adenovirus vectors to the muscle
48. Immunogenecity of enhanced green fluorescent protein (EGFP) in BALB/c mice: Identification of an H2-Kd-restricted CTL epitope
49. Immune response to green fluorescent protein: Implications for gene therapy